Co-sleeping mothers at higher risk of developing depression, new study claims

Agencies
March 2, 2018

Washington, Mar 2: Turns out, mothers who co-sleep with infants beyond six months may feel more depressed and judged by others.

According to a Penn State-study, mothers who choose to co-sleep with their infants are more likely to feel depressed or judged when faced with recent trends and popular advice telling moms not to sleep with their babies.

After analyzing moms' sleeping patterns and feelings about sleep for the first year of their babies' lives, the researchers found that mothers who were still co-sleeping - sharing either a room or bed - with their infants after six months were more likely to feel depressed, worried about their babies' sleep and think their decisions were being criticized.

Douglas Teti of the Penn State said that regardless of current parenting trends, it's important to find a sleep arrangement that works for everyone in the family.

"In other parts of the world, co-sleeping is considered normal, while here in the U.S., it tends to be frowned upon," Teti said. "Co-sleeping, as long as it is done safely, is fine as long as both parents are on board with it. If it's working for everyone, and everyone is okay with it, then co-sleeping is a perfectly acceptable option."

The researchers said that while most American families begin co-sleeping when their babies are first born, most of those families transition the babies to their own room by the time he or she is six months old. Teti said concerns about sudden infant death syndrome (SIDS) or the desire for babies to learn how to fall asleep on their own may be why many parents in the U.S. prefer their babies to be sleep alone.

Teti said this study - which analysed the sleeping habits of 103 mothers in their baby's first year of life - saw a similar pattern in its participants. "We found that about 73 percent of families co-slept at the one-month point. That dropped to about 50 percent by three months, and by six months, it was down to about 25 percent," Teti said. "Most babies that were in co-sleeping arrangements in the beginning were moved out into solitary sleep by six months."

On average, mothers that were still co-sleeping after six months reported feeling about 76 percent more depressed than mothers who had moved their baby into a separate room. They also reportedly felt about 16 percent more criticised or judged for their sleep habits.

"We definitely saw that the persistent co-sleepers -- the moms that were still co-sleeping after six months -- were the ones who seemed to get the most criticism," Teti said. "Additionally, they also reported greater levels of worry about their baby's sleep, which makes sense when you're getting criticized about something that people are saying you shouldn't be doing, that raises self-doubt. That's not good for anyone."

Teti said that the study isn't about whether co-sleeping is good or bad, but about the importance of finding a sleep arrangement that works well while not neglecting your partner or spouse.

"If you're going to co-sleep, you have to make sure both people in the partnership have talked it through and both people are in sync with what they want to do," Teti said. "If not, that's when criticism and arguments can happen and possibly spill over into the relationship with child. So you want to avoid that. You need to make sure you have time with your partner, as well."

Teti also said that even when co-sleeping works well, it can still cause more loss of sleep for the parents than if the baby slept in its own room.

"If you co-sleep, it is going to disrupt your sleep, and probably Mom's sleep more than Dad's," Teti said. "So this is something to be careful with if you're not good with chronic sleep debt. Co-sleeping needs to work well for everyone, and that includes getting adequate sleep. To be the best parent you can be, you have to take care of yourself, and your child benefits as a result", concluded Teti.

The study is published in the journal Infant and Child Development.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 26,2020

Tedros Adhanom Ghebreyesus, the World Health Organisation's (WHO) Director-General, said that a clinical trial of hydroxychloroquine (HCQ) on COVID-19 patients has come to "a temporary pause", while the safety data of the the anti-malaria drug was being reviewed.

According to the WHO chief, The Lancet medical journal on May 22 had published an observational study on HCQ and chloroquine and its effects on COVID-19 patients that have been hospitalized, reports Xinhua news agency.

The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

"The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally," Tedros said in a virtual press conference on Monday.

The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug, he said.

"The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing," Tedros added.

WHO initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include HCQ.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tedros added that the safety concern over the drug related only to the use of HCQ and chloroquine in COVID-19, and "these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria".

"WHO will provide further updates as we know more," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 6,2020

Researchers have found the rates of lung cancer are higher in young women than men.

The study, published in the journal Pediatrics, examined lung cancer rates in young adults in 40 countries across five continents and uncovered a trend of higher lung cancer rates in women compared with men in recent years.

The emerging trend was widespread, affecting countries across varied geographic locations and income levels.

The changes appeared to be driven by a rising rate of adenocarcinoma lung cancer among women, said the study researchers from University of Calgary in Canada.

Lung cancer rates have been higher among men than women because men started smoking in large numbers earlier and smoked at higher rates; however, recent studies have reported converging lung cancer incidence rates between sexes.

Among men, age specific lung cancer incidence rates generally decreased in all countries, while in women the rates varied across countries with the trends in most countries stable or declining, albeit at a slower pace compared to those in men.

For the findings, lung and bronchial cancer cases between 30-64 age group from 1993-2012 were extracted from cancer incidence in five continents.

The study found the higher emerging rates of lung cancer in young women compared to young men.

According to the researchers, future studies are needed to identify reasons for the elevated incidence of lung cancer among young women.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
April 14,2020

There is no evidence that the Bacille Calmette-Guerin (BCG) vaccine, which is primarily used against tuberculosis, protects people against infection with the novel coronavirus, the World Health Organization (WHO) said.

The WHO therefore didn't recommend BCG vaccination for the prevention of COVID-19 in the absence of evidence, according to its daily situation report on Monday, Xinhua news agency reported.

"There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance remains unknown," WHO stated.

Two clinical trials addressing the question are underway, and WHO will evaluate the evidence when it is available, it noted.

BCG vaccination prevents severe forms of tuberculosis in children and diversion of local supplies may result in an increase of disease and deaths from the tuberculosis, it warned.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.